Please assess the completion status of the following clinical trial:

Trial Title: Everolimus and Docetaxel in Treating Patients With Recurrent, Locally Advanced, or Metastatic Head and Neck Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed squamous cell carcinoma of the head and neck~  * Locally advanced or metastatic disease~    * No patients with locally advanced disease for whom radiotherapy is indicated~ * Recurrent disease~ * Incurable disease~* Measurable disease by RECIST criteria~  * Recurrent disease within a prior radiation field can be considered to be measurable~* Patients may have received 1 line of prior chemotherapy (but not a taxane) for locally advanced or metastatic disease~* Patients may have received prior radiation therapy for locally advanced or metastatic disease (but must have completed the radiotherapy \> 6 months before recruitment)~  * No disease relapsed within 6 months of radiotherapy~* No evidence of central nervous system metastases~PATIENT CHARACTERISTICS:~* ECOG performance status 0-1~* Life expectancy ≥ 12 weeks~* Absolute neutrophil count ≥ 1,500/mm³~* Platelet count ≥ 100,000/mm³~* Hemoglobin ≥ 10 g/dL~* Urea and creatinine normal~* Serum bilirubin normal~* AST or ALT ≤ 1.5 times upper limit of normal (ULN)~* Alkaline phosphatase \< 2.5 times ULN~* Negative pregnancy test~* Not pregnant or nursing~* Fertile patients must use effective contraception during and for 3 months (female) or 2 months (male) after the last dose of the study treatment~* No uncontrolled infection~* No mental condition rendering the patient unable to understand the nature, scope, and possible consequences of the study~* No prior malignancy likely to interfere with the patient's ability to comply with treatment and/or follow up~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* No prior chemotherapy for any cancer, except for head and neck cancer~* No prior taxane~* No prior therapy with any erbB inhibitors (except cetuximab given with radiotherapy, as indicated in treatment algorithm)~* More than 6 months since prior radiotherapy for locally advanced or metastatic disease~* At least 4 weeks since prior investigational drug~* No concurrent use of drugs known to inhibit CYP3A4 (except dexamethasone), or block P-glycoprotein, including grapefruit juice~* No other concurrent chemotherapy, immunotherapy, hormonal cancer therapy, radiotherapy, or experimental medications~* No concurrent live vaccines during everolimus therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).